702 related articles for article (PubMed ID: 21163137)
41. Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.
Kotani D; Yoshino T; Kotaka M; Kawazoe A; Masuishi T; Taniguchi H; Yamazaki K; Yamanaka T; Oki E; Muro K; Komatsu Y; Bando H; Satake H; Kato T; Tsuji A
Invest New Drugs; 2021 Dec; 39(6):1649-1655. PubMed ID: 34019214
[TBL] [Abstract][Full Text] [Related]
42. Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11.
Di Leo A; Buyse M; Bleiberg H
Ann Oncol; 2004 Apr; 15(4):545-9. PubMed ID: 15033657
[TBL] [Abstract][Full Text] [Related]
43. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
Scheithauer W; Kornek GV; Schuell B; Ulrich-Pur H; Penz M; Raderer M; Lang F; Schneeweiss B; Lenauer A; Depisch D
Ann Oncol; 2001 May; 12(5):709-14. PubMed ID: 11432632
[TBL] [Abstract][Full Text] [Related]
44. [Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma].
Kang SH; Kim JI; Moon HS; Kim SH; Sung JK; Lee BS; Jeong HY
Korean J Gastroenterol; 2010 Jan; 55(1):26-32. PubMed ID: 20098064
[TBL] [Abstract][Full Text] [Related]
45. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
[TBL] [Abstract][Full Text] [Related]
46. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E
Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502
[TBL] [Abstract][Full Text] [Related]
47. Second line therapies move to the forefront in colorectal cancer.
Miller M
J Natl Cancer Inst; 1999 Jun; 91(12):998-1000. PubMed ID: 10379961
[No Abstract] [Full Text] [Related]
48. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
49. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Fischer von Weikersthal L; Schalhorn A; Stauch M; Quietzsch D; Maubach PA; Lambertz H; Oruzio D; Schlag R; Weigang-Köhler K; Vehling-Kaiser U; Schulze M; Truckenbrodt J; Goebeler M; Mittermüller J; Bosse D; Szukics B; Grundeis M; Zwingers T; Giessen C; Heinemann V
Eur J Cancer; 2011 Jan; 47(2):206-14. PubMed ID: 20971632
[TBL] [Abstract][Full Text] [Related]
50. Raltitrexed-based chemotherapy for advanced colorectal cancer.
Liu Y; Wu W; Hong W; Sun X; Wu J; Huang Q
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):219-25. PubMed ID: 24388340
[TBL] [Abstract][Full Text] [Related]
51. Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.
McWilliams RR; Goetz MP; Morlan BW; Salim M; Rowland KM; Krook JE; Ames MM; Erlichman C
Clin Colorectal Cancer; 2007 May; 6(7):516-21. PubMed ID: 17553200
[TBL] [Abstract][Full Text] [Related]
52. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
53. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
Bajetta E; Beretta E; Di Bartolomeo M; Cortinovis D; Ferrario E; Dognini G; Toffolatti L; Buzzoni R
Oncology; 2004; 66(2):132-7. PubMed ID: 15138365
[TBL] [Abstract][Full Text] [Related]
55. Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802).
Suenaga M; Nishina T; Mizunuma N; Yasui H; Ura T; Denda T; Ikeda J; Esaki T; Nishisaki H; Takano Y; Sugiyama Y; Muro K
BMC Cancer; 2015 Mar; 15():176. PubMed ID: 25884814
[TBL] [Abstract][Full Text] [Related]
56. Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer.
Zhuang L; Bai J; Huang H; Tang C; Yang J; Zhou B; Gong Y; Duanmu Z; Chen J
Oncol Res; 2010; 18(9):437-44. PubMed ID: 20524401
[TBL] [Abstract][Full Text] [Related]
57. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
58. Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.
Gkioulbasanis I; Souglakos J; Vardakis N; Kotsakis A; Saridaki Z; Kentepozidis N; Polyzos A; Giassas S; Ignatiadis M; Bozionelou V; Christophylakis C; Georgoulias V
J BUON; 2007; 12(2):197-202. PubMed ID: 17600872
[TBL] [Abstract][Full Text] [Related]
59. Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.
Fernandes GDS; Braghiroli MI; Artioli M; Paterlini ACCR; Teixeira MC; Gumz BP; Girardi DDM; Braghiroli OFM; Costa FP; Hoff PM
J Gastrointest Cancer; 2018 Dec; 49(4):470-475. PubMed ID: 28884286
[TBL] [Abstract][Full Text] [Related]
60. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F
Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
